ARDS - Cerecor surges after announcing Phase 2 data for monoclonal antibody in COVID-19

Cerecor Inc. (CERC) has climbed ~11.3% in the pre-market after announcing final efficacy data from a Phase 2 trial for the monoclonal antibody, CERC-002 in patients hospitalized with COVID-19 associated pneumonia and mild to moderate acute respiratory distress syndrome (ARDS).In the recently completed US-based, multi-center trial, a total of 83 patients on standard of care were randomized 1:1 to receive a single dose of 1,200 mg of CERC-002 or placebo, subcutaneously.The trial has met its primary endpoint of the proportion of patients alive and free of respiratory failure over the 28-day study period compared to placebo (n=62, p=0.044) with efficacy being highest in a subpopulation of those over the age of 60 (n=34, p=0.042).At both the 28-day and the 60-day final timepoints, a ~50% trend in mortality reduction (22.5% vs 10.8%) was also observed.CERC-002 was well-tolerated with no drug-related serious adverse effects (SAEs) and no increase in infections in CERC-002 treated patients.“These results are

For further details see:

Cerecor surges after announcing Phase 2 data for monoclonal antibody in COVID-19